EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Beijing Enterprises Medical and Health Industry Group Ltd (2389) fair value: what the stock is really worth

As of Sep 30, 2026: fair value of Beijing Enterprises Medical and Health Industry Group Ltd HK$0.15, price HK$0.08, upside +96.3%, quality 43 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Healthcare · HK · ISIN KYG0957Q1082

BE Thin data Sep 27, 2026

Beijing Enterprises Medical and Health Industry Group Ltd

2389 · HK

Cheap, value-trap riskThe stock looks deeply undervalued, but low quality raises value-trap risk.

✓Fair value HK$0.1531 · Strongly undervalued (+96.3%)
!Quality 43/100
!Weak Growth (revenue 5y +1.0 %/yr)
!Loss-making · -64.2% net margin (TTM)
!Low debt · negative free cash flow
!Mixed vs. peers (4/9)
!Narrow moat 1/100
!Evidence only low, so the estimate is less certain
!Weak on future: 26 out of 100
Watch Beijing Enterprises Medical and Health Industry Group Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$0.1450 HK$0.0600 Fair Value HK$0.1531 May 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.

How to read this chart

60‑month range HK$0.0600 – HK$0.1450 · fair‑value band HK$0.1207 – HK$0.2260 · the HK$0.0780 price screens below the HK$0.1531 fair value. Dashed = 300-day average. As of Sep 27, 2026.

Follow Beijing Enterprises Medical and Health Industry Group in your weekly email

Every Wednesday you see whether Beijing Enterprises Medical and Health Industry Group is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Beijing Health (Holdings) Limited, an investment holding company, provides medical, health, and geriatric care related services and products in the People's Republic of China.

Show more

Beijing Health (Holdings) Limited, an investment holding company, provides medical, health, and geriatric care related services and products in the People's Republic of China. It engages in the investment and operation of general health industrial park; sports and health sector; and incubator projects; sports businesses, which includes construction and operation of stadiums for winter sports; and investment in the field of the biotechnology, pharmaceutical, medical services, and medical travel. The company also provides investment management consulting services; and engages in trading geriatric care related furniture. In addition, it is involved in medical and logistics related property development activities. The company was formerly known as Beijing Enterprises Medical and Health Industry Group Limited and changed its name to Beijing Health (Holdings) Limited in June 2021. Beijing Health (Holdings) Limited was founded in 1995 and is headquartered in Cheung Sha Wan, Hong Kong.

Stock analysis

Beijing Enterprises Medical and Health Industry Group Ltd (2389) currently trades at HK$0.0780, while our model-based Fair Value estimate is HK$0.1531, implying the stock looks roughly 49.1% undervalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 88/100, which puts the evidence level at low.

Scenario range: HK$0.1207 (bear) to HK$0.2260 (bull), the price of HK$0.0780 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak: less than 2 % a year.

Beijing Enterprises Medical and Health Industry Group Ltd reported revenue of HK$157M in FY2025 versus HK$204M in FY2021, a compound −6.3%/yr. Reported net income was −HK$101M in FY2025.

Key figures

Market cap HK$473M (≈ $60.2M) · P/S ratio 2.93 · Net margin −64.2% · Return on equity −5.8% · Return on assets (EBIT) −3.6% · Operating margin −29.7% · Revenue (TTM) HK$157M · Revenue growth (YoY) +5.2%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).

What moves the price

The share trades about 8% below its 52-week high and 30% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 21% fair-value upside, at 96%, 2389 screens cheaper than that median.

Fair Value models

Bear HK$0.1207 Fair Value HK$0.1531 Bull HK$0.2260
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) HK$0.1400 HK$0.1800 HK$0.2700 54
All 1 models by family
Asset-Based
NCAV (Graham) HK$0.1400 HK$0.1800 HK$0.2700 54

Open the full fair value analysis →

Notify me when 2389 reaches fair value

Put 2389 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 43/100

Of which business quality 42 · Market factors (momentum, volatility) 54

Profitability 1
Margins and returns on capital today
Quality Growth 65
Are margins and returns improving?
Cashflow 1
Earnings quality: real cash, not paper profit
Fin. Strength 55
Balance sheet, leverage, solvency risk
Investment 89
Disciplined investing over empire-building
Low Volatility 70
Calm price path (market factor)
Momentum 48
Price trend over the last 3–12 months (market factor)
52W Momentum 46
Distance to the 52-week high (market factor)
Net Issuance 82
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 5/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+4.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.0%
Start year 2020 (pandemic)
Revenue growth 25 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−88.3% (2020) → −63.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch 2389, get fair value alerts →

Compare Beijing Enterprises Medical and Health Industry Group Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 249 stocks

Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 42 · Bottom 25%
Fair Value upside +96.3% · Top 25%
Profitability
Return on assets −1.7% · Bottom 25%
Net margin (TTM) −64.2% · Bottom 25%
Operating margin (TTM) −29.7% · Bottom 25%
Growth and dividend
Revenue growth 5.2% · Above median

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/S (TTM) 0.38× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 33
FUTURE (revenue growth)26 · sector 26
PAST (return on equity)0 · sector 30
HEALTH (low debt)100 · sector 89
DIVIDEND (yield)0 · sector 41

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
HCA Healthcare, Inc HCA $431.63 $597.97 +39%
Fresenius SE FRE €46.15 €34.49 −25%
Dr. Sulaiman Al Habib Medical Services Group 4013 225.00 SAR 109.45 SAR −51%
Tenet Healthcare Corporation THC $257.93 $274.35 +6%
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,889 ₹2,908 −67%
Encompass Health Corporation EHC $123.47 $94.47 −23%
Fresenius Medical Care AG FMS $22.27 $45.84 +106%
DaVita Inc DVA $178.07 $215.81 +21%
Aier Eye Hospital Group 300015 ¥7.91 ¥10.86 +37%
Universal Health Services, Inc UHS $175.73 $444.19 +153%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Beijing Enterprises Medical and Health Industry Group Ltd · Fair Value
HK$0.1531 +49%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Beijing Enterprises Medical and Health Industry Group Ltd Fair Value". https://www.fairvalue-calculator.com/stock/2389

Frequently asked questions

Is Beijing Enterprises Medical and Health Industry Group Ltd (2389) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of HK$0.1531 versus a price of HK$0.0780, about +96% upside (undervalued).
What is the fair value of 2389?
Our model-based fair value for Beijing Enterprises Medical and Health Industry Group Ltd is HK$0.1531 (as of Sep 27, 2026), built from audited fundamentals. The current price: HK$0.0780.
What is the quality score of 2389?
Beijing Enterprises Medical and Health Industry Group Ltd has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Beijing Enterprises Medical and Health Industry Group Ltd (2389)?
Our model-based price target is the fair value of HK$0.1531 (as of Sep 27, 2026) from 1 valuation models. Cautious scenario HK$0.1207, optimistic scenario HK$0.2260. It is a calculation from audited fundamentals, not an analyst target.
What is the Beijing Enterprises Medical and Health Industry Group Ltd stock forecast for 2026?
Our models put fair value at HK$0.1531, about +96% upside versus a price of HK$0.0780 (undervalued). Cautious scenario HK$0.1207, optimistic scenario HK$0.2260. The calculation is refreshed regularly with new filings.
What is the revenue of Beijing Enterprises Medical and Health Industry Group Ltd (2389)?
Beijing Enterprises Medical and Health Industry Group Ltd reported trailing-twelve-month revenue of about HK$157M (latest available figure, as of Sep 27, 2026).
What is the intrinsic value of Beijing Enterprises Medical and Health Industry Group Ltd (2389)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Beijing Enterprises Medical and Health Industry Group Ltd it is HK$0.1531 per share (as of Sep 27, 2026), against a price of HK$0.0780. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Beijing Enterprises Medical and Health Industry Group Ltd stock overvalued or undervalued in 2026?
As of Sep 27, 2026, 2389 trades below its calculated fair value: price HK$0.0780, fair value HK$0.1531, a gap of about +96% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2389?
No. The price is what the market pays today (HK$0.0780); the fair value is what the company's own numbers justify (HK$0.1531). For Beijing Enterprises Medical and Health Industry Group Ltd the two are HK$0.0751 per share apart. That gap is exactly why we show both numbers side by side.
How much is Beijing Enterprises Medical and Health Industry Group Ltd worth?
The market values Beijing Enterprises Medical and Health Industry Group Ltd at about HK$473M (market capitalisation, as of Sep 27, 2026). Per share that is HK$0.0780; our models calculate a fair value of HK$0.1531 per share.
What do the bullish and bearish scenarios say about 2389?
Our models span a range for Beijing Enterprises Medical and Health Industry Group Ltd: cautious scenario HK$0.1207, base HK$0.1531, optimistic HK$0.2260 per share (as of Sep 27, 2026, price HK$0.0780). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Beijing Enterprises Medical and Health Industry Group Ltd (2389)?
Balance-sheet figures for Beijing Enterprises Medical and Health Industry Group Ltd (as of Sep 27, 2026): return on equity −5.8%. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
How far is 2389 from its 52-week high?
Beijing Enterprises Medical and Health Industry Group Ltd trades at HK$0.0780, about 8% below its 52-week high of HK$0.0850 and 30% above the low of HK$0.0600 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.1531 is for.
Which stocks are comparable to Beijing Enterprises Medical and Health Industry Group Ltd?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, Tenet Healthcare Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Beijing Enterprises Medical and Health Industry Group Ltd stock attractive at the current price?
The data as of Sep 27, 2026: price HK$0.0780, calculated fair value HK$0.1531 (+96%), Quality Score 43/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 2389 calculated?
We run Beijing Enterprises Medical and Health Industry Group Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$0.1531, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.7 % above its aggregate fair value. Beijing Enterprises Medical and Health Industry Group Ltd currently trades 49 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Beijing Enterprises Medical and Health Industry Group Ltd (2389)?
The closing price on Sep 30, 2026 was HK$0.0780. Our model-based fair value is HK$0.1531, about +96% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Beijing Enterprises Medical and Health Industry Group Ltd right now?
The large discount to fair value meets weak quality (43/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (HK$0.1207). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (HK$0.1207 to HK$0.2260) leaves room in how you read the outcome.

Key figures of Beijing Enterprises Medical and Health Industry Group Ltd

How large is the market capitalisation of Beijing Enterprises Medical and Health Industry Group Ltd (2389)?
The market capitalisation of Beijing Enterprises Medical and Health Industry Group Ltd is HK$473M (≈ $60.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Beijing Enterprises Medical and Health Industry Group Ltd (2389)?
The price-to-sales ratio of Beijing Enterprises Medical and Health Industry Group Ltd is 2.93 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Beijing Enterprises Medical and Health Industry Group Ltd (2389)?
The net margin of Beijing Enterprises Medical and Health Industry Group Ltd is −64.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Beijing Enterprises Medical and Health Industry Group Ltd (2389)?
The return on equity (ROE) of Beijing Enterprises Medical and Health Industry Group Ltd is −5.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Beijing Enterprises Medical and Health Industry Group Ltd (2389)?
On an EBIT basis the return on assets of Beijing Enterprises Medical and Health Industry Group Ltd is −3.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Beijing Enterprises Medical and Health Industry Group Ltd (2389)?
The operating margin of Beijing Enterprises Medical and Health Industry Group Ltd is −29.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Beijing Enterprises Medical and Health Industry Group Ltd (2389)?
Revenue at Beijing Enterprises Medical and Health Industry Group Ltd is growing +5.2% versus a year earlier (3y avg −1.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Beijing Enterprises Medical and Health Industry Group Ltd (2389) generate?
The free cash flow of Beijing Enterprises Medical and Health Industry Group Ltd is −HK$18.0M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Beijing Enterprises Medical and Health Industry Group Ltd (2389) hold?
Beijing Enterprises Medical and Health Industry Group Ltd holds more cash than debt, HK$26.4M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Beijing Enterprises Medical and Health Industry Group Ltd in the live analysis

One click puts Beijing Enterprises Medical and Health Industry Group Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.